Bryan Goldman

803 total citations
11 papers, 514 citations indexed

About

Bryan Goldman is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Bryan Goldman has authored 11 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Molecular Biology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Bryan Goldman's work include Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (5 papers) and Pharmacology and Obesity Treatment (2 papers). Bryan Goldman is often cited by papers focused on Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (5 papers) and Pharmacology and Obesity Treatment (2 papers). Bryan Goldman collaborates with scholars based in Denmark, United States and United Kingdom. Bryan Goldman's co-authors include Thomas A. Wadden, Ildiko Lingvay, Domenica Rubino, Dror Dicker, Melanie J. Davies, Mette S. Thomsen, Sean Wharton, Salvatore Calanna, Ofri Mosenzon and Neil R Poulter and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Diabetes Care.

In The Last Decade

Bryan Goldman

10 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bryan Goldman Denmark	7	415	208	203	116	73	11	514
Juan José Gorgojo Martínez Spain	12	465 1.1×	186 0.9×	167 0.8×	166 1.4×	96 1.3×	30	586
Burkhard Goeke Germany	6	405 1.0×	104 0.5×	146 0.7×	201 1.7×	71 1.0×	13	513
Fred Yang United States	9	771 1.9×	166 0.8×	386 1.9×	300 2.6×	50 0.7×	17	867
P Andréadis Greece	6	298 0.7×	64 0.3×	154 0.8×	87 0.8×	57 0.8×	14	402
Laura Heenan United States	4	471 1.1×	114 0.5×	165 0.8×	138 1.2×	59 0.8×	7	532
Masakazu Takeuchi Japan	13	479 1.2×	130 0.6×	256 1.3×	128 1.1×	72 1.0×	29	550
Irene Caruso Italy	15	371 0.9×	82 0.4×	181 0.9×	124 1.1×	71 1.0×	28	527
P. Miossec France	12	991 2.4×	204 1.0×	455 2.2×	376 3.2×	83 1.1×	22	1.1k
Trine Saugstrup Denmark	6	405 1.0×	124 0.6×	284 1.4×	98 0.8×	54 0.7×	8	611
Desirée Thielke Denmark	8	613 1.5×	176 0.8×	373 1.8×	122 1.1×	94 1.3×	12	701

Countries citing papers authored by Bryan Goldman

Since Specialization

Citations

This map shows the geographic impact of Bryan Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Goldman more than expected).

Fields of papers citing papers by Bryan Goldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Goldman. The network helps show where Bryan Goldman may publish in the future.

Co-authorship network of co-authors of Bryan Goldman

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan Goldman. A scholar is included among the top collaborators of Bryan Goldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan Goldman. Bryan Goldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Arslanian, Silva, Inge Gies, Bryan Goldman, et al.. (2025). Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care.

Kushner, Robert F., Anders Fink‐Jensen, Barbara McGowan, et al.. (2023). Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis. Obesity. 32(2). 273–280. 5 indexed citations

Goldman, Bryan, et al.. (2021). Evaluation of Consistency of Treatment Response Across Regions—the LEADER Trial in Relation to the ICH E17 Guideline. Frontiers in Medicine. 8. 662775–662775. 4 indexed citations

Wharton, Sean, Salvatore Calanna, Melanie J. Davies, et al.. (2021). Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obesity and Metabolism. 24(1). 94–105. 92 indexed citations

Marso, Steven P., Florian M.M. Baeres, Stephen C. Bain, et al.. (2020). Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. Journal of the American College of Cardiology. 75(10). 1128–1141. 74 indexed citations

Kushner, Robert F., Salvatore Calanna, Melanie J. Davies, et al.. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 28(6). 1050–1061. 200 indexed citations

Zobel, Emilie H., Bernt Johan von Scholten, Bryan Goldman, et al.. (2019). Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. Diabetes Obesity and Metabolism. 21(5). 1261–1265. 10 indexed citations

Husain, Mansoor, Stephen C. Bain, Johannes F.E. Mann, et al.. (2018). NO INCREASED RISK OF HEART FAILURE HOSPITALIZATION OR MAJOR CARDIOVASCULAR EVENTS OBSERVED WITH LIRAGLUTIDE IN PATIENTS WITH OR WITHOUT A HISTORY OF NEW YORK HEART ASSOCIATION CLASS II-III HEART FAILURE: RESULTS FROM THE LEADER TRIAL. Journal of the American College of Cardiology. 71(11). A673–A673. 7 indexed citations

Husain, Mansoor, S. Bain, Johannes F.E. Mann, et al.. (2018). P2518Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events. European Heart Journal. 39(suppl_1). 4 indexed citations

10.

Mann, Johannes F.E., Vivian Fonseca, Ofri Mosenzon, et al.. (2018). Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 138(25). 2908–2918. 98 indexed citations

11.

Négrier, Claude, Guy Young, Faraizah Abdul Karim, et al.. (2016). Recombinant long‐acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia. 22(4). 507–513. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact